On 15 June 2026, Celltrion announced that it has launched its rituximab and bevacizumab biosimilars in Vietnam. Truxima®, biosimilar to Roche/Genentech/Biogen’s Rituxan®/MabThera® (rituximab), and Vegzelma™, biosimilar to Roche/Genentech’s Avastin® (bevacizumab) were launched by Celltrion on 9 June 2026, following receipt of marketing authorisation three months earlier.
Celltrion now has four biosimilars on the market in Vietnam, having previously launched Remsima® (infliximab) and Herzuma® (trastuzumab) in August 2025. Celltrion plans to leverage marketing synergies between the four products to accelerate prescriptions and is planning to introduce follow-up products into the Vietnamese market, including Remsima® SC.
Rituximab was one of the first mAbs to become “biosimilar”, being first approved in the US on 26 November 1997. There are three rituximab biosimilars currently on the US market: Teva and Celltrion’s Truxima® (launched in May 2020), Pfizer’s Ruxience® (launched in January 2020) and Amgen and Allergan’s RiabniTM (approved by the FDA in December 2020).
The first bevacizumab biosimilar approved in the US was Amgen’s Mvasi® in September 2017, with Mvasi® also being approved in Europe in January 2018. There are currently five other bevacizumab biosimilars approved in the US: Pfizer’s Zirabev® (June 2019), Amneal’s Alymsys® (April 2022), Celltrion’s Vegzelma™ (September 2022), Bio-Thera/Sandoz’s Avzivi® (December 2023), and Biocon Biologics’ Jobevne™ (April 2025). More recently, on 13 January 2026, Shanghai Henlius Biotech announced that a Biologics Licence Application (BLA) for its bevacizumab biosimilar, HLX04, was accepted for review by the FDA.